Phillip Securities lifts C&O Pharmaceutical (E92.SG) target price to $0.65 from $0.53, implying 13.7x FY11 P/E, after increasing FY11 earnings estimate by 8.6% to HK$175 million ($30.5 million) to assume stronger growth across all business segments, contributions from roll-out of new drugs, keeping Buy call, according to Dow Jones.
Phillip expects new drug Edaravone, used to aid neurological recovery, to be major earnings driver in coming years considering fewer than five manufacturers in China capable of producing it.
Broker notes market for this drug, which C&O expects to get regulatory approval for mass production by October, worth about RMB1 billion ($200 million) in 2009. Shares flat at $0.465.
Monday, August 30, 2010
C&O Pharma target raised to $0.65 by Phillip Securities
As reported at
Subscribe to:
Post Comments (Atom)
Popular Posts
-
新加坡人口400万，亚洲人口4亿，全世界人口6亿。 但是，我一人可能就很有可能是世界最傻的了。我真是个不折不扣的大木头。真是受不了自己。
-
Ever found yourself staring at a folder full of files and wishing you could batch append them all with a .txt suffix? PowerShell makes this ...
-
I would like to apologize that sigining of my guestbook is not possible at the moment due to an unexpected bug. There is already 74 entries ...
-
*********** Try to sleep now, close your eyes Soon the birds would stop singing Twinkling stars, are shining bright They'll be watch...
-
#2013 in review:- Work) Little change » Status quo. Life) Pursued » Achieved. I know #2014 will be very different.
No comments:
Post a Comment
Do provide your constructive comment. I appreciate that.